Client of a consultant lobbyist
GlaxoSmithKline Inc.
- Meetings this Parliament
- 4
- With MPs
- 0
- Since Nov 2021
- 4
- Active registrations
- 1
Most recent reported meeting: Jul 27, 2026.
Lobbying by GlaxoSmithKline Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
Consultant In effect since Jul 22, 2026
Consultant Danielle Flieler of Santis Health
Consultant lobbyists
- Danielle Flieler
- Danielle Flieler
Institutions they may lobby: Canadian Heritage (PCH), Health Canada (HC), House of Commons, Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Justice Canada (JC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)
What they're lobbying on (13)Hide details
- Seek funding and support for pilot projects making anti-infective medications available to equity seeking populations, helping to combat AMR.
- The Government of Ontario has passed legislation requiring the public disclosure of payments made to Health Care Providers and Health Care Organizations by the broader health care industry, including pharmaceutical companies, generic manufacturers, and medical device companies. GlaxoSmithKline seeks to advocate for a national approach to disclosure through either the support of similar provincial initiatives, coordinated action through the Federal / Provincial and Territorial meetings of the Ministers of Health, and / or the establishment of national requirements.
- Sharing information with government and Members of Parliament on different models for national pharmacare, specifically as it relates to access to medicines.
- Renewal of national vaccine strategy to close gaps in vaccination coverage for Canadians, especially among seniors.
- Reforms to the Patented Medicines Review Board (PMPRB), whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Specifically with regard to ensuring that any actions and proposed changes by the PMPRB do not negatively impact access to patented medicines in Canada.
- Raise awareness regarding the potential risks to drug and vaccine supply for Canadian patients arising from new U.S. state-level reimportation legislation.
- Participation in consultations regarding the Digital Charter and the federal government's plans to overhaul Canada's privacy regime, to enable the use of anonymized health data for new medication research and development.
- Input on the work of the Advisory Committee on the Implementation of National Pharmacare, specifically as it relates to access to medicines.
- Ensure the National Advisory Committee on Immunization has sufficient resources to undertake timely reviews of new vaccines that are made available to the Canadian marketplace.
- Engaging Health Canada on the Self-Care Products Initiative as it pertains to plain language labelling and a risk-based approach to regulatory oversight for non prescription drugs.
- Engage with government to strengthen the Priority Review of Drug Submissions process.
- Engage government officials regarding domestic manufacturing of seasonal and pandemic flu vaccine.
- Antimicrobial Resistance (AMR) - Identification of the need for a multi-sectoral stakeholder working group to pursue joint goals under a Pan-Canadian AMR strategy and to strengthen Canada's end-to-end research capacity in AMR.
Registration 953997-384612-2. Look it up in the official Registry
Reported meetings
Spreadsheet-
Reported by Danielle Flieler · Consultant
- Justine Frame · Policy Advisor, Health Canada (HC)
Engage government officials regarding domestic manufacturing of seasonal and pandemic flu vaccine. Read more
Renewal of national vaccine strategy to close gaps in vaccination coverage for Canadians, especially among seniors.
-
Reported by Danielle Flieler · Consultant
- Justine Frame · Policy Advisor, Health Canada (HC)
Engage government officials regarding domestic manufacturing of seasonal and pandemic flu vaccine.
-
Reported by Danielle Flieler · Consultant
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Engage government officials regarding domestic manufacturing of seasonal and pandemic flu vaccine. Read more
Seek funding and support for pilot projects making anti-infective medications available to equity seeking populations, helping to combat AMR.
Antimicrobial Resistance (AMR) - Identification of the need for a multi-sectoral stakeholder working group to pursue joint goals under a Pan-Canadian AMR strategy and to strengthen Canada's end-to-end research capacity in AMR.
-
Reported by Danielle Flieler · Consultant
- Justine Frame · Special Assistant, Policy, Health Canada (HC)
Engage with government to strengthen the Priority Review of Drug Submissions process. Read more
Renewal of national vaccine strategy to close gaps in vaccination coverage for Canadians, especially among seniors.
Raise awareness regarding the potential risks to drug and vaccine supply for Canadian patients arising from new U.S. state-level reimportation legislation.
Engage government officials regarding domestic manufacturing of seasonal and pandemic flu vaccine.
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.